induced pluripotent stem cell (iPSC)

Search documents
Century Therapeutics to Present at Chardan's 9th Annual Genetic Medicines Conference
Globenewswire· 2025-10-14 20:01
PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today announced that Chad Cowan, Ph.D., Chief Scientific Officer of Century Therapeutics, will present at Chardan’s 9th Annual Genetic Medicines Conference on Tuesday, October 21, 2025, at 12:20 p.m. ET in New York, NY. A live webcast of the presentation will be available on the ...
Century Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference
Globenewswire· 2025-10-14 20:01
PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today announced that Chad Cowan, Ph.D., Chief Scientific Officer of Century Therapeutics, will present at Chardan’s 9th Annual Genetic Medicines Conference on Tuesday, October 21, 2025, at 12:20 p.m. ET in New York, NY. A live webcast of the presentation will be available on the ...
Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus
ZACKS· 2025-05-14 16:45
Financial Performance - Fate Therapeutics reported a loss of 32 cents per share for Q1 2025, which is narrower than the Zacks Consensus Estimate of a loss of 39 cents, and an improvement from a loss of 47 cents per share in the same period last year [1] - The company earned collaboration revenues of $1.6 million, exceeding the Zacks Consensus Estimate of $1 million, although revenues declined by 15.8% year-over-year [1] - Research and development (R&D) expenses decreased by 9.3% to $29.1 million, while general and administrative (G&A) expenses decreased by approximately 34% to $13.8 million [4] - As of March 31, 2025, cash, cash equivalents, and investments totaled $272.7 million, which is expected to sustain operations through the first half of 2027 [4] Stock Performance - Shares of Fate Therapeutics increased by 5% in after-hours trading on May 13, following the better-than-expected earnings announcement [2] - Year-to-date, the stock has declined by 39.4%, compared to the industry's decline of 6.4% [3] Pipeline Development - Fate Therapeutics is focused on developing universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform, which includes iPSC-derived natural killer (NK) cells and T-cell product candidates [5] - A phase I study of FT819, a T-cell product candidate for systemic lupus erythematosus (SLE), is ongoing, with dose expansion initiated in up to 10 patients at 360 million cells [6][8] - The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to FT819 for treating active moderate to severe SLE, including lupus nephritis [9] - Fate Therapeutics is co-developing FT825/ONO-8250, a multiplexed-engineered, iPSC-derived CAR T-cell product candidate, with ONO Pharmaceutical, and is conducting a phase I study for advanced solid tumors [9][10]